In short
IPN01195 is a novel investigational medication currently being studied for the treatment of advanced solid tumors. This first-in-human clinical trial aims to evaluate the safety, appropriate dosing, and effectiveness of IPN01195 in adult patients whose cancer has progressed to advanced stages. The study is designed in two phases: Phase I to determine the optimal dose and Phase II to further assess the drug's anti-tumor activity. This article provides an overview of the ongoing clinical research with IPN01195, helping patients understand what this experimental treatment involves and how the clinical trial is structured.
Key points
- IPN01195 is a novel investigational drug currently being studied in a Phase I/II clinical trial for patients with advanced solid tumors. The trial is designed to determine the optimal dose of IPN01195, evaluate its safety profile, and assess its effectiveness in treating cancer. The study consists of dose escalation (testing different doses), dose confirmation (evaluating selected doses further), and potentially a Phase II component to further explore anti-tumor activity. Researchers are measuring multiple outcomes including how the body processes the drug, whether tumors respond to treatment, and how long patients remain without disease progression. The clinical trial requires regular visits for assessments with tumor evaluations conducted every 6-12 weeks throughout the study period.
At a glance
- Drug Name
- IPN01195
- Study Type
- Phase I/II, First-in-human, Open-label
- Target Condition
- Advanced solid tumors
- Study Structure
- Phase I (Parts A and B) followed by Phase II
- Primary Objectives
- Determine safety, tolerability, appropriate dosage, and anti-tumor activity
- Key Measurements
- Safety profile, tumor response rates, progression-free survival, duration of response
- Assessment Schedule
- Tumor evaluations every 6 weeks (first 24 weeks), then every 12 weeks
- Treatment Duration
- Up to approximately 3 years, depending on response and tolerability
- Follow-up Evaluation
- 30 days after the last dose of study medication
What is IPN01195?
IPN01195 is a new investigational medication that is currently being studied for the treatment of advanced solid tumors. This drug is in the early stages of clinical development, specifically in a Phase I/II clinical trial, which means it is not yet approved for general use. The trial represents the first time this medication is being tested in humans (known as a first-in-human study).
What Conditions Does IPN01195 Treat?
IPN01195 is being investigated for the treatment of advanced solid tumors. These are cancers that:
- Form in solid organs or tissues (as opposed to blood cancers)
- Have spread from their original site to nearby tissues (locally advanced)
- May have spread to other parts of the body (metastatic)
The current clinical trial is not limited to a specific type of solid tumor, suggesting that researchers are investigating the drug's potential effectiveness across multiple cancer types.
Clinical Trial Design
The clinical trial for IPN01195 (identified as NCT06833008) is structured as an open-label, Phase I/II study. "Open-label" means that both the participants and researchers know which treatment is being given. The study is divided into two main phases:
Phase I
This initial phase is further split into two parts:
- Part A (Dose Escalation): This part aims to find the safe dose range that shows activity against tumors. Different dose levels will be tested to determine how much of the drug patients can tolerate.
- Part B (Dose Confirmation): After finding potentially effective doses in Part A, this segment will further assess how the drug works at either a "low dose" or "high dose" level. Participants will be randomly assigned to one of these dose groups.
Phase II
Based on the results from Phase I, the study will continue to a Phase II extension. This phase will further evaluate the drug's effectiveness and safety at the optimal dose determined in the earlier phase.
How IPN01195 is Administered
The clinical trial documents indicate that IPN01195 will be administered at assigned dose levels, though the specific route of administration (such as oral or intravenous) is not explicitly stated in the available information. However, since the study includes food effect assessments (comparing the drug's absorption when taken with or without food), it's likely that IPN01195 is administered orally.
Safety Assessment
A primary focus of this clinical trial is to evaluate the safety of IPN01195. Several safety measurements are being tracked:
- Dose-Limiting Toxicities (DLTs): These are side effects serious enough to prevent increasing the dose further. The study measures the percentage of participants experiencing DLTs within 28 days of their first dose.
- Treatment Emergent Adverse Events (TEAEs): These are any unfavorable medical occurrences that begin after starting the study medication, whether or not they're believed to be related to the drug.
- Serious Adverse Events: These are more severe side effects that may require hospitalization or are life-threatening.
- Dose Interruptions and Treatment Discontinuations: The study tracks how often treatment needs to be paused or stopped completely due to side effects.
- QT Interval Prolongation: The study monitors for potential effects on heart rhythm, specifically looking at the QT interval (a measurement on an electrocardiogram that indicates how long it takes for the heart to recharge between beats).
How Effectiveness is Being Measured
The study uses several standard measurements to assess how well IPN01195 works against cancer:
- Objective Response Rate (ORR): This is the percentage of participants whose tumors shrink or disappear completely. A "complete response" means all detectable cancer has disappeared, while a "partial response" means the tumor has shrunk by a defined percentage.
- Duration of Response (DoR): For patients whose tumors do respond to treatment, this measures how long that response lasts before the cancer starts growing again.
- Progression-Free Survival (PFS): This is the time from starting treatment until the cancer starts growing again or the patient dies.
- PFS Rate at 4 Months: The proportion of participants who are still alive and whose cancer has not progressed 4 months after starting treatment.
- Disease Control Rate (DCR): This includes patients whose best response is complete response, partial response, or stable disease (tumor neither growing nor shrinking significantly).
Food Effects on IPN01195
Part of the study evaluates how food affects the way the body processes IPN01195. This assessment compares:
- How quickly the drug reaches its maximum concentration in the blood (Tmax)
- The highest concentration it reaches (Cmax)
- The total exposure to the drug over time (AUC - Area Under the Curve)
These measurements are compared when the drug is taken in a fasted state (without food) versus a fed state (with food). This information helps determine whether future patients should take the medication with or without food for optimal effectiveness.
What to Expect as a Trial Participant
Participants in the IPN01195 clinical trial can expect:
- Screening Period: Initial assessments to determine eligibility for the study.
- Treatment Period: At least two visits during the first month, followed by monthly visits.
- Tumor Assessments: Every 6 weeks up to Week 24, then every 12 weeks afterward to measure how the tumor is responding to treatment.
- End of Treatment Visit: Occurring 30 days after the last dose of the study drug.
- Monitoring Procedures: Regular blood samples, urine collections, physical examinations, and clinical evaluations throughout the study.
The total duration of the study may be up to approximately 3 years, depending on how well participants respond to the treatment.